Cutera (CUTR) Issues FY18 Earnings Guidance

Cutera (NASDAQ:CUTR) updated its FY18 earnings guidance on Wednesday. The company provided EPS guidance of $1.03-1.11 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.00. The company issued revenue guidance of $178-181 million, compared to the consensus revenue estimate of $166.90 million.

Several equities analysts recently weighed in on the stock. Zacks Investment Research cut shares of Cutera from a hold rating to a sell rating in a research report on Monday, January 1st. BidaskClub raised shares of Cutera from a hold rating to a buy rating in a research report on Tuesday, December 12th. Finally, Maxim Group reaffirmed a hold rating on shares of Cutera in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Cutera currently has an average rating of Buy and an average price target of $37.33.

Cutera (NASDAQ CUTR) traded up $0.70 during trading on Thursday, hitting $46.65. 171,100 shares of the company’s stock traded hands, compared to its average volume of 171,513. Cutera has a 1 year low of $18.50 and a 1 year high of $52.90. The company has a market cap of $636.64, a PE ratio of 59.81, a P/E/G ratio of 1.37 and a beta of 0.41.

Cutera (NASDAQ:CUTR) last posted its earnings results on Wednesday, February 14th. The medical device company reported $0.42 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.09. Cutera had a net margin of 7.99% and a return on equity of 18.73%. The firm had revenue of $47.60 million for the quarter, compared to analysts’ expectations of $43.96 million. During the same quarter last year, the firm earned $0.30 EPS. The company’s quarterly revenue was up 25.6% compared to the same quarter last year. research analysts anticipate that Cutera will post 0.55 earnings per share for the current fiscal year.

In other Cutera news, EVP Miguel Pardos sold 10,000 shares of Cutera stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $46.70, for a total transaction of $467,000.00. Following the transaction, the executive vice president now owns 39,698 shares of the company’s stock, valued at approximately $1,853,896.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David B. Apfelberg sold 1,000 shares of Cutera stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $47.40, for a total transaction of $47,400.00. Following the transaction, the director now directly owns 8,259 shares in the company, valued at approximately $391,476.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,018 shares of company stock worth $1,147,316. Insiders own 11.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply